Mirum CEO exercises options and sells 20,000 shares
Mirum Pharmaceuticals, Inc. CEO Christopher Peetz exercised an employee stock option for 20,000 shares of common stock at an exercise price of $2.936 per share and received 20,000 shares on August 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Mirum Pharmaceuticals, Inc. CEO Christopher Peetz exercised an employee stock option for 20,000 shares of common stock at an exercise price of $2.936 per share and received 20,000 shares on August 10, 2026. On the same date he sold a total of 20,000 common shares in three tranches at weighted average prices of $98.51, $99.25, and $100.14 per share pursuant to a Rule 10b5-1 Plan. Following the option exercise, he reported 88,487 stock options remaining and an indirect holding of 187,500 shares held by The Peetz Family Trust.
Insider Trade Summary 10b5-1
Exercise and Sale: 20,000 shares ($1.92M approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Peetz Christopher
Role
CHIEF EXECUTIVE OFFICER
Sold
20,000 shs ($1.98M)
Approx. gross sale proceeds
$1.98M
Approx. exercise cost
$59K
Approx. pre-tax spread
$1.92M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F5 | 20,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 20,000 | $2.936 | $59K |
| Sale | Common Stock F1, F2 | 11,683 | $98.51 | $1.15M |
| Sale | Common Stock F1, F3 | 6,017 | $99.25 | $597K |
| Sale | Common Stock F1, F4 | 2,300 | $100.14 | $230K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 88,487 contracts (Direct);
Common Stock — 194,309 shares (Direct);
Common Stock — 187,500 shares (Indirect, By The Peetz Family Trust)
Footnotes (5)
- F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026.
- F2. The weighted average sale price for the transaction reported was $98.51, and the range of prices were between $97.93 and $98.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3. The weighted average sale price for the transaction reported was $99.25, and the range of prices were between $98.94 and $99.655. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4. The weighted average sale price for the transaction reported was $100.14, and the range of prices were between $99.995 and $100.2425. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F5. The stock option is fully vested.
Key Figures
Options Exercised: 20,000 shares
Exercise Price: $2.936 per share
Shares Sold Tranche 1: 11,683 shares at $98.51
+5 more
8 metrics
Options Exercised
20,000 shares
Employee Stock Option exercised on August 10, 2026 at $2.936 per share
Exercise Price
$2.936 per share
Exercise price for 20,000 Employee Stock Options
Shares Sold Tranche 1
11,683 shares at $98.51
Weighted average sale price; prices between $97.93 and $98.92
Shares Sold Tranche 2
6,017 shares at $99.25
Weighted average sale price; prices between $98.94 and $99.655
Shares Sold Tranche 3
2,300 shares at $100.14
Weighted average sale price; prices between $99.995 and $100.2425
Options Remaining After Exercise
88,487 shares
Stock options reported following the derivative transaction
Indirect Trust Holdings
187,500 shares
Common stock held indirectly by The Peetz Family Trust
Option Expiration
March 11, 2029
Expiration date of the exercised Employee Stock Option
Key Terms
Rule 10b5-1 Plan, Employee Stock Option, weighted average sale price, indirect ownership, +1 more
5 terms
Rule 10b5-1 Plan regulatory
"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Employee Stock Option financial
"security_title: "Employee Stock Option (right to buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
weighted average sale price financial
"The weighted average sale price for the transaction reported was $98.51"
indirect ownership financial
"ownership_type":"indirect","ownership_code":"I""
fully vested financial
"The stock option is fully vested."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Mirum Pharmaceuticals (MIRM) CEO Christopher Peetz report in this Form 4?
Christopher Peetz reported exercising 20,000 stock options at $2.936 per share and selling 20,000 common shares in three transactions on August 10, 2026, under a Rule 10b5-1 Plan.
What option exercise did the Mirum Pharmaceuticals (MIRM) CEO report?
He exercised an Employee Stock Option for 20,000 shares of Mirum common stock at an exercise price of $2.936 per share; the option was disclosed as fully vested and expires on March 11, 2029.
Were the Mirum Pharmaceuticals (MIRM) CEO’s stock sales under a Rule 10b5-1 plan?
Yes. A footnote states the reported sales occurred pursuant to a Rule 10b5-1 Plan adopted by Christopher Peetz on March 2, 2026, and the filing’s 10b5-1 checkbox is affirmed.
What Mirum Pharmaceuticals (MIRM) holdings does the CEO report after these transactions?
After exercising options, he reports 88,487 options remaining directly and an indirect holding of 187,500 common shares held by The Peetz Family Trust, in addition to his direct stock position reflected in the sales.
What is the nature of the indirect Mirum Pharmaceuticals (MIRM) holdings reported?
The filing lists 187,500 common shares held indirectly by The Peetz Family Trust. This entry reports total shares held through the trust as of August 10, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates